GEP201706690B - Novel process for making compounds for use in treatment of cancer - Google Patents

Novel process for making compounds for use in treatment of cancer

Info

Publication number
GEP201706690B
GEP201706690B GEAP201313824A GEAP2013013824A GEP201706690B GE P201706690 B GEP201706690 B GE P201706690B GE AP201313824 A GEAP201313824 A GE AP201313824A GE AP2013013824 A GEAP2013013824 A GE AP2013013824A GE P201706690 B GEP201706690 B GE P201706690B
Authority
GE
Georgia
Prior art keywords
cancer
treatment
novel process
making compounds
compounds
Prior art date
Application number
GEAP201313824A
Other languages
English (en)
Inventor
Sriram Naganathan
Nathan Guz
Matthew Pfeiffer
C Gregory Sowell
Tracy Bostick
Jason Yang
Amit Srivastava
Original Assignee
Exelixis Inc
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc, Genentech Inc filed Critical Exelixis Inc
Publication of GEP201706690B publication Critical patent/GEP201706690B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
GEAP201313824A 2012-10-12 2013-10-14 Novel process for making compounds for use in treatment of cancer GEP201706690B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261713104P 2012-10-12 2012-10-12

Publications (1)

Publication Number Publication Date
GEP201706690B true GEP201706690B (en) 2017-06-26

Family

ID=49474740

Family Applications (1)

Application Number Title Priority Date Filing Date
GEAP201313824A GEP201706690B (en) 2012-10-12 2013-10-14 Novel process for making compounds for use in treatment of cancer

Country Status (31)

Country Link
US (4) US9771347B2 (en:Method)
EP (1) EP2909188B1 (en:Method)
JP (2) JP6300042B2 (en:Method)
KR (1) KR102204520B1 (en:Method)
CN (2) CN104837826B (en:Method)
AU (1) AU2013328929B2 (en:Method)
BR (1) BR112015008113B1 (en:Method)
CA (1) CA2889466C (en:Method)
CL (1) CL2015000926A1 (en:Method)
CR (2) CR20200237A (en:Method)
EA (1) EA030613B1 (en:Method)
ES (1) ES2671502T3 (en:Method)
GE (1) GEP201706690B (en:Method)
HK (1) HK1213567A1 (en:Method)
HR (1) HRP20180670T1 (en:Method)
IL (1) IL238116B (en:Method)
IN (1) IN2015DN03928A (en:Method)
MA (1) MA38085B1 (en:Method)
MX (2) MX372708B (en:Method)
MY (1) MY186549A (en:Method)
NZ (1) NZ706723A (en:Method)
PE (3) PE20191818A1 (en:Method)
PH (1) PH12015500785A1 (en:Method)
PL (1) PL2909188T3 (en:Method)
SA (1) SA515360271B1 (en:Method)
SG (1) SG11201502795VA (en:Method)
SI (1) SI2909188T1 (en:Method)
TR (1) TR201807861T4 (en:Method)
UA (1) UA115455C2 (en:Method)
WO (1) WO2014059422A1 (en:Method)
ZA (1) ZA201502349B (en:Method)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR201807861T4 (tr) 2012-10-12 2018-06-21 Exelixis Inc Kanser tedavisinde kullanım için bileşikler yapmak için yeni işlem.
US9532987B2 (en) 2013-09-05 2017-01-03 Genentech, Inc. Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases
AR105483A1 (es) 2015-06-30 2017-10-11 Exelixis Inc Sal de fumarato cristalina de (s)-[3,4-difluoro-2-(2-fluoro-4-yodofenilamino)fenil][3-hidroxi-3-(piperidin-2-il)azetidin-1-il]-metanona
CN108135854B (zh) 2015-06-30 2022-03-11 基因泰克公司 含有药物的立即释放片剂和用于形成片剂的方法
CN105330643B (zh) * 2015-12-09 2017-12-05 苏州明锐医药科技有限公司 卡比替尼的制备方法
CN106045969B (zh) * 2016-05-27 2019-04-12 湖南欧亚药业有限公司 一种卡比替尼的合成方法
CN109689102A (zh) 2016-08-12 2019-04-26 基因泰克公司 Mek抑制剂,pd-1轴抑制剂,和vegf抑制剂的组合疗法
KR20190061030A (ko) 2016-09-29 2019-06-04 제넨테크, 인크. Mek 억제제, pd-1 축 억제제 및 탁산을 사용한 조합 요법
WO2020187674A1 (en) 2019-03-15 2020-09-24 Sandoz Ag Crystalline (s)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl][3-hydroxy-3-(piperidin-2-yl)azetidin-1-yl]methanone hemisuccinate
CN117940130A (zh) 2021-03-09 2024-04-26 基因泰克公司 用于脑癌治疗的贝伐拉非尼
US20240366609A1 (en) 2021-04-06 2024-11-07 Genentech, Inc. Combination therapy with belvarafenib and cobimetinib or with belvarafenib, cobimetinib, and atezolizumab

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1563587A (en) * 1924-09-20 1925-12-01 Raney Murray Method of preparing catalytic material
US1628190A (en) * 1926-05-14 1927-05-10 Raney Murray Method of producing finely-divided nickel
US1915473A (en) * 1930-12-31 1933-06-27 Raney Murray Method of preparing catalytic material
US4510139A (en) 1984-01-06 1985-04-09 Sterling Drug Inc. Substituted aminobenzamides and their use as agents which inhibit lipoxygenase activity
US5155110A (en) 1987-10-27 1992-10-13 Warner-Lambert Company Fenamic acid hydroxamate derivatives having cyclooxygenase and 5-lipoxygenase inhibition
AU685933B2 (en) 1994-04-01 1998-01-29 Shionogi & Co., Ltd. Oxime derivative and bactericide containing the same as active ingredient
AU6966696A (en) 1995-10-05 1997-04-28 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
WO1998037881A1 (en) 1997-02-28 1998-09-03 Warner Lambert Company Method of treating or preventing septic shock by administering a mek inhibitor
US6310060B1 (en) * 1998-06-24 2001-10-30 Warner-Lambert Company 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors
EP0993437B1 (en) * 1997-07-01 2006-11-08 Warner-Lambert Company Llc 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as mek inhibitors
WO1999001426A1 (en) 1997-07-01 1999-01-14 Warner-Lambert Company 4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as mek inhibitors
US6974878B2 (en) 2001-03-21 2005-12-13 Symyx Technologies, Inc. Catalyst ligands, catalytic metal complexes and processes using same
EP1140046A1 (en) 1998-12-15 2001-10-10 Warner-Lambert Company Use of a mek inhibitor for preventing transplant rejection
HUP0104693A3 (en) 1998-12-16 2003-12-29 Warner Lambert Co Treatment of arthritis with mek inhibitors
HK1042057A1 (zh) 1998-12-22 2002-08-02 沃尼尔‧朗伯公司 联合化学疗法
KR20000047461A (ko) 1998-12-29 2000-07-25 성재갑 트롬빈 억제제
CA2350234A1 (en) 1999-01-07 2000-07-13 Alexander James Bridges Treatment of asthma with mek inhibitors
WO2000040237A1 (en) 1999-01-07 2000-07-13 Warner-Lambert Company Antiviral method using mek inhibitors
EE200100373A (et) 1999-01-13 2002-10-15 Warner-Lambert Company Bensoheterotsüklid ja nende kasutamine MEK inhibiitoritena
CA2348236A1 (en) 1999-01-13 2000-07-20 Stephen Douglas Barrett 4-arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective mek inhibitors
AU2201500A (en) 1999-01-13 2000-08-01 Warner-Lambert Company Benzenesulfonamide derivatives and their use as mek inhibitors
AU2483400A (en) 1999-01-13 2000-08-01 Warner-Lambert Company 4'heteroaryl diarylamines
CA2355374A1 (en) 1999-01-13 2000-07-20 Warner-Lambert Company 1-heterocycle substituted diarylamines
IL147150A0 (en) 1999-07-16 2002-08-14 Warner Lambert Co Method for treating chronic pain using mek inhibitors
DE60005688T2 (de) 1999-07-16 2004-04-29 Warner-Lambert Co. Llc Verfahren zur behandlung von chronischem schmerz durch verabreichung von einem mek hemmer
AU5786000A (en) 1999-07-16 2001-02-05 Warner-Lambert Company Method for treating chronic pain using mek inhibitors
CN1358095A (zh) 1999-07-16 2002-07-10 沃尼尔·朗伯公司 使用mek抑制剂治疗慢性疼痛的方法
MX226123B (es) 1999-09-17 2005-02-07 Millennium Pharm Inc Benzamidas e inhibidores del factor xa relacionadas.
MXPA02008103A (es) 2000-03-15 2002-11-29 Warner Lambert Co Diarilaminas sustituidas con 5-amida como inhibidores mek.
AR033517A1 (es) 2000-04-08 2003-12-26 Astrazeneca Ab Derivados de piperidina, proceso para su preparacion y uso de estos derivados en la fabricacion de medicamentos
CN1219753C (zh) 2000-07-19 2005-09-21 沃尼尔·朗伯公司 4-碘苯氨基苯氧肟酸的氧合酯
IL154507A0 (en) * 2000-08-25 2003-09-17 Warner Lambert Co Process for making n-aryl-anthranilic acids and their derivatives
US7105682B2 (en) 2001-01-12 2006-09-12 Amgen Inc. Substituted amine derivatives and methods of use
IL149462A0 (en) 2001-05-09 2002-11-10 Warner Lambert Co Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor
US20040039208A1 (en) * 2001-07-20 2004-02-26 Chen Michael Huai Gu Process for making n-aryl-anthranilic acids and their derivatives
DE10141266A1 (de) 2001-08-21 2003-03-06 Syntec Ges Fuer Chemie Und Tec Elektrolumineszierende Derivate der 2,5-Diamino-terephthalsäure und deren Verwendung in organischen Leuchtdioden
US7085492B2 (en) 2001-08-27 2006-08-01 Ibsen Photonics A/S Wavelength division multiplexed device
MXPA04002539A (es) 2001-10-31 2004-05-31 Pfizer Prod Inc Combatientes de los receptores de la acetilcolina nicotinica en el tratamiento del sindrome de pierna inquietas.
DOP2003000556A (es) 2002-01-23 2003-10-31 Warner Lambert Co Esteres hidroxamato de acido n-(4-fenil-sustituido)-antranilico.
WO2003062191A1 (en) 2002-01-23 2003-07-31 Warner-Lambert Company Llc N-(4-substituted phenyl)-anthranilic acid hydroxamate esters
IL163996A0 (en) 2002-03-13 2005-12-18 Array Biopharma Inc N3 alkylated benzimidazole derivatives as mek inhibitors
US7235537B2 (en) 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
ATE449605T1 (de) 2002-03-13 2009-12-15 Array Biopharma Inc N3-alkylierte benzimidazol-derivate als mek- hemmer
WO2003103590A2 (en) 2002-06-11 2003-12-18 Merck & Co., Inc. (halo-benzo carbonyl)heterobicyclic p38 kinase inhibiting agents
GB0214268D0 (en) 2002-06-20 2002-07-31 Celltech R&D Ltd Chemical compounds
WO2004004644A2 (en) 2002-07-05 2004-01-15 Beth Israel Deaconess Medical Center Combination of mtor inhibitor and a tyrosine kinase inhibitor for the treatment of neoplasms
US20050004186A1 (en) 2002-12-20 2005-01-06 Pfizer Inc MEK inhibiting compounds
JP4617299B2 (ja) 2003-03-03 2011-01-19 アレイ バイオファーマ、インコーポレイテッド p38阻害剤及びその使用法
TW200505834A (en) 2003-03-18 2005-02-16 Sankyo Co Sulfamide derivative and the pharmaceutical composition thereof
JP2005162727A (ja) 2003-03-18 2005-06-23 Sankyo Co Ltd スルファミド誘導体及びその医薬組成物
GB0308185D0 (en) 2003-04-09 2003-05-14 Smithkline Beecham Corp Novel compounds
EA010297B1 (ru) 2003-06-20 2008-08-29 ЮСиБи ФАРМА С.А. Производные тиенопиридона как ингибиторы киназ
WO2005000818A1 (en) 2003-06-27 2005-01-06 Warner-Lambert Company Llc 5-substituted-4-`(substituted phenyl)!amino!-2-pyridone deviatives for use as mek inhibitors
US20050049276A1 (en) 2003-07-23 2005-03-03 Warner-Lambert Company, Llc Imidazopyridines and triazolopyridines
WO2005009975A2 (en) 2003-07-24 2005-02-03 Warner-Lambert Company Llc Benzimidazole derivatives as mek inhibitors
US7538120B2 (en) 2003-09-03 2009-05-26 Array Biopharma Inc. Method of treating inflammatory diseases
US7144907B2 (en) 2003-09-03 2006-12-05 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
JP4931419B2 (ja) 2003-09-19 2012-05-16 中外製薬株式会社 新規4−フェニルアミノ−ベンズアルドオキシム誘導体並びにそのmek阻害剤としての使用
NZ547481A (en) 2003-11-19 2009-12-24 Array Biopharma Inc Heterocyclic inhibitors of mek and methods of use thereof
US7517994B2 (en) 2003-11-19 2009-04-14 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
RU2361868C2 (ru) 2003-12-08 2009-07-20 Ф.Хоффманн-Ля Рош Аг Новые производные тиазола
TWI361066B (en) 2004-07-26 2012-04-01 Chugai Pharmaceutical Co Ltd 5-substituted-2-phenylamino benzamides as mek inhibitors
SI1802579T1 (sl) * 2004-10-20 2014-03-31 Merck Serono Sa Derivati 3-arilaminopiridina
WO2006061712A2 (en) 2004-12-10 2006-06-15 Pfizer Inc. Use of mek inhibitors in treating abnormal cell growth
US7547782B2 (en) 2005-09-30 2009-06-16 Bristol-Myers Squibb Company Met kinase inhibitors
CA3052368A1 (en) * 2005-10-07 2007-04-19 Exelixis, Inc. Azetidines as mek inhibitors
EP2056829B9 (en) 2006-08-16 2012-09-26 Exelixis, Inc. Using pi3k and mek modulators in treatments of cancer
JP5311673B2 (ja) * 2006-12-14 2013-10-09 エグゼリクシス, インコーポレイテッド Mek阻害剤の使用方法
TR201807861T4 (tr) 2012-10-12 2018-06-21 Exelixis Inc Kanser tedavisinde kullanım için bileşikler yapmak için yeni işlem.
ES2702891T3 (es) 2014-02-07 2019-03-06 Sumitomo Chemical Co Método para producir (R)-1,1,3-Trimetil-4-aminoindano
AR105483A1 (es) 2015-06-30 2017-10-11 Exelixis Inc Sal de fumarato cristalina de (s)-[3,4-difluoro-2-(2-fluoro-4-yodofenilamino)fenil][3-hidroxi-3-(piperidin-2-il)azetidin-1-il]-metanona

Also Published As

Publication number Publication date
AU2013328929A1 (en) 2015-04-30
US20170349569A1 (en) 2017-12-07
PH12015500785B1 (en) 2015-06-15
HK1213878A1 (en) 2016-07-15
MY186549A (en) 2021-07-26
CL2015000926A1 (es) 2015-08-28
TR201807861T4 (tr) 2018-06-21
EA030613B1 (ru) 2018-08-31
WO2014059422A1 (en) 2014-04-17
CR20200237A (es) 2020-07-26
JP2018052973A (ja) 2018-04-05
UA115455C2 (uk) 2017-11-10
CA2889466C (en) 2021-09-14
CN108948043B (zh) 2021-05-04
IN2015DN03928A (en:Method) 2015-10-02
MA38085B1 (fr) 2018-11-30
US20190185447A1 (en) 2019-06-20
CN104837826B (zh) 2018-07-27
SG11201502795VA (en) 2015-05-28
MX2015004660A (es) 2015-08-07
PL2909188T3 (pl) 2018-08-31
NZ706723A (en) 2018-07-27
US10239858B2 (en) 2019-03-26
JP6300042B2 (ja) 2018-03-28
JP2015533175A (ja) 2015-11-19
EP2909188A1 (en) 2015-08-26
CA2889466A1 (en) 2014-04-17
ZA201502349B (en) 2019-12-18
US11414396B2 (en) 2022-08-16
US20150210668A1 (en) 2015-07-30
BR112015008113B1 (pt) 2022-05-24
CN104837826A (zh) 2015-08-12
MA38085A1 (fr) 2018-08-31
PH12015500785A1 (en) 2015-06-15
KR20150067339A (ko) 2015-06-17
BR112015008113A2 (pt) 2017-07-04
IL238116B (en) 2018-06-28
US20200392104A1 (en) 2020-12-17
ES2671502T3 (es) 2018-06-06
EP2909188B1 (en) 2018-03-07
PE20200387A1 (es) 2020-02-24
PE20191818A1 (es) 2019-12-27
CN108948043A (zh) 2018-12-07
HK1213567A1 (zh) 2016-07-08
MX2020005533A (es) 2020-10-12
US10793541B2 (en) 2020-10-06
SA515360271B1 (ar) 2016-05-19
CR20150245A (es) 2015-11-19
SI2909188T1 (en) 2018-07-31
MX372708B (es) 2020-05-29
HRP20180670T1 (hr) 2018-07-13
PE20151494A1 (es) 2015-11-06
AU2013328929B2 (en) 2018-01-04
KR102204520B1 (ko) 2021-01-20
US9771347B2 (en) 2017-09-26
EA201590700A1 (ru) 2015-09-30

Similar Documents

Publication Publication Date Title
GEP201706690B (en) Novel process for making compounds for use in treatment of cancer
TN2014000138A1 (en) Substituted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases.
MY177344A (en) Compounds and their methods of use
EA201400178A1 (ru) Лечение рака молочной железы
PH12014501258A1 (en) Pyrazolopyridine derivatives, preparation process therefor and therapeutic use thereof
MX2013010898A (es) Novedoso derivados de la pirimidina.
NZ700612A (en) Methods and compositions for treating ewings sarcoma family of tumors
MX2014012477A (es) Inhibidores pirrolopirazona de tanquirasa.
MX354024B (es) Uso de array-380 y ar00440993 para el tratamiento de cancer de cerebro.
NZ711192A (en) Process for making benzoxazepin compounds
PH12015501088A1 (en) Dimeric compounds
MX346095B (es) Nuevas imidazol-aminas como moduladores de la actividad de cinasas.
MX2016008259A (es) Metodo de proceso para inhibidores de fosfatidilinositol 3-cinasa.
GEP201706626B (en) Synthesis of (s)-nifuratel
NI201200195A (es) Procedimiento de preparación de la sal de l - arginina de perindoprilo
PH12014501712B1 (en) Novel morpholinyl derivatives useful as mogat-2-inhibitors
GB201107985D0 (en) Process
MX2013014488A (es) Metodos y composiciones para tratar el cancer cerebral.
PH12015500061A1 (en) Method for preparing substituted triazolopyridines
IN2013MU01113A (en:Method)
GB201209015D0 (en) Novel compounds
TN2015000095A1 (en) Macrolide derivatives, preparation thereof and therapeutic use thereof
EA033160B1 (ru) Соединения для лечения заболеваний, связанных с ишемией-реперфузией
MX2015007460A (es) Agentes para el tratamiento del dolor y usos de los mismos.
NZ715554A (en) Method of treating hypertrophic cardiomyopathy